After watching and looking through the E.U.
Posts Tagged failed-the
Biotehc firm Rigel’s (RIGL) rheumatoid arthritis drug candidate R788 did not meet its primary endpoint in Phase IIb clinical trial, probably putting in question the company’s goal of securing a R788 partner by the first half of 2010. In a odd twist, the main reason R788 failed the efficacy portion of the 219-patient study is because [[ This is a content summary only.
